Structure-Based virtual screening and de novo design of PIM1 inhibitors with anticancer activity from natural products
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwangseo Park | - |
dc.contributor.author | Jinwon Jeon | - |
dc.contributor.author | Kewon Kim | - |
dc.contributor.author | Soyeon Choi | - |
dc.contributor.author | Sungwoo Hong | - |
dc.date.accessioned | 2021-04-27T07:30:14Z | - |
dc.date.accessioned | 2021-04-27T07:30:14Z | - |
dc.date.available | 2021-04-27T07:30:14Z | - |
dc.date.available | 2021-04-27T07:30:14Z | - |
dc.date.created | 2021-04-26 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://pr.ibs.re.kr/handle/8788114/9551 | - |
dc.description.abstract | © 2021 by the authors. Background: the proviral insertion site of Moloney murine leukemia (PIM) 1 kinase has served as a therapeutic target for various human cancers due to the enhancement of cell proliferation and the inhibition of apoptosis. Methods: to identify effective PIM1 kinase inhibitors, structurebased virtual screening of natural products of plant origin and de novo design were carried out using the protein-ligand binding free energy function improved by introducing an adequate dehydration energy term. Results: as a consequence of subsequent enzyme inhibition assays, four classes of PIM1 kinase inhibitors were discovered, with the biochemical potency ranging from low-micromolar to sub-micromolar levels. The results of extensive docking simulations showed that the inhibitory activity stemmed from the formation of multiple hydrogen bonds in combination with hydrophobic interactions in the ATP-binding site. Optimization of the biochemical potency by chemical modifications of the 2-benzylidenebenzofuran-3(2H)-one scaffold led to the discovery of several nanomolar inhibitors with antiproliferative activities against human breast cancer cell lines. Conclusions: these new PIM1 kinase inhibitors are anticipated to serve as a new starting point for the development of anticancer medicine. | - |
dc.description.uri | 1 | - |
dc.language | 영어 | - |
dc.publisher | MDPI AG | - |
dc.title | Structure-Based virtual screening and de novo design of PIM1 inhibitors with anticancer activity from natural products | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.identifier.wosid | 000634076300001 | - |
dc.identifier.scopusid | 2-s2.0-85103132684 | - |
dc.identifier.rimsid | 75463 | - |
dc.contributor.affiliatedAuthor | Jinwon Jeon | - |
dc.contributor.affiliatedAuthor | Kewon Kim | - |
dc.contributor.affiliatedAuthor | Soyeon Choi | - |
dc.contributor.affiliatedAuthor | Sungwoo Hong | - |
dc.identifier.doi | 10.3390/ph14030275 | - |
dc.identifier.bibliographicCitation | Pharmaceuticals, v.14, no.3 | - |
dc.citation.title | Pharmaceuticals | - |
dc.citation.volume | 14 | - |
dc.citation.number | 3 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordAuthor | Anticancer activity | - |
dc.subject.keywordAuthor | De novo design | - |
dc.subject.keywordAuthor | Natural products | - |
dc.subject.keywordAuthor | PIM1 | - |
dc.subject.keywordAuthor | Virtual screening | - |